cAMP-response element-binding protein and heat-shock protein 70 additively suppress polyglutamine-mediated toxicity

Kanae Iijima-Ando1, Priscilla Wu, Eric A Drier

  • 1Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, NY 11724, USA. iijmaka@cshl.edu

Insights

Cyclic AMP-response element-binding protein (CREB) plays a role in polyglutamine toxicity, a hallmark of neurodegenerative diseases. Targeting CREB and heat-shock protein 70 may offer new therapeutic avenues for these conditions.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Polyglutamine (polyQ) diseases, such as Huntington's disease, are linked to CAG repeat expansions.
  • Transcriptional dysregulation is a proposed mechanism underlying polyQ-induced neurotoxicity.
  • The role of specific transcription factors in polyQ pathogenesis remains to be fully elucidated.

Purpose of the Study:

  • To investigate the involvement of Cyclic AMP-response element-binding protein (CREB) in polyglutamine toxicity.
  • To explore the interaction between CREB and heat-shock protein 70 (Hsp70) in mitigating polyQ-induced neurodegeneration.

Main Methods:

  • Utilized Drosophila melanogaster as a model organism to study polyglutamine toxicity.
  • Assessed the impact of mutations and gene copy number variations in the Drosophila CREB homolog (dCREB2) on polyQ-induced lethality.
  • Measured CRE-mediated transcription using a reporter gene assay in neurons expressing expanded polyglutamine peptides.

Main Results:

  • A mutation in dCREB2 exacerbated polyglutamine-induced lethality, while an extra copy of dCREB2 partially rescued it.
  • Neuronal expression of expanded polyglutamine attenuated in vivo CRE-mediated transcription.
  • Overexpression of Hsp70 rescued polyglutamine lethality but did not restore CREB-mediated transcription.

Conclusions:

  • CREB is implicated in the toxicity associated with expanded polyglutamine peptides.
  • The protective mechanisms of CREB and Hsp70 against polyglutamine toxicity operate through distinct pathways.
  • Combined therapeutic strategies targeting both CREB and Hsp70 pathways may be beneficial for treating polyglutamine diseases.

Related Concept Videos